According to the World Health
Organization (WHO), cervical cancer is the second most commonly
prevalent cancer and the third greatest cause of death in women, with
530,000 new cases discovered each year. Increasing number of
HIV-infected individuals and suppressed immune system are the primary
factors contributing to the growth of the global cervical cancer
diagnostic tests market. Furthermore, increasing incidences of sexual
contact with an infected individual or multiple partners, long-term use
of contraceptive pills and certain genetic factors have contributed to
the growth of the cervical cancer diagnostic tests market. However,
recently, the number of deaths related to cervical cancer has decreased
marginally due to rising awareness about various cervical cancer
diagnostic tests such as Pap smear tests and HPV tests. Hence,
increasing awareness about the screening and treatment of cervical
cancer is expected to boost the growth of the market in the next few
years.
Report Overview @ https://www.transparencymarketresearch.com/cervical-cancer-diagnostic-tests-market.html
The global cervical cancer diagnostics
tests market is segmented by test types into Pap smear tests,
colopscopy, HPV testing, endocervical curettage (ECC) procedure and
others, which includes cone biopsy and loop electrosurgical excision
procedure (LEEP). HPV testing segment accounted for the fastest growing
segment in the overall market. Factors that have contributed to the high
growth of the segment are increasing rate of HPV infection among
individuals across geographies, rising incidences of sexually
transmittable infections and increasing incidences of smoking.
Additionally, most HPV-infected women develop certain mild abnormalities
related to the cervix, which would boost the growth of the HPV testing
segment. The Pap smear tests segment is also estimated to grow at a CAGR
of more than 6% during the forecast period from 2014 to 2020. The major
driving factors for such remarkable growth of the segment are early
detection of glandular cell abnormalities through Pap smear test that
can be further treated immediately and increasing need among female
population for prognosis as well as diagnosis of cervical cancer. Hence,
early monitoring of cervical cancer in women has contributed to the
high growth of the Pap smear tests segment. Demand for other tests such
as colopscopy, ECC, LEEP is growing at an equivalent rate due to high
incidences and prevalence of cervical cancer.
Request A Sample Copy @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=736
Geographically, North America was the
largest market for cervical cancer diagnostic tests in 2013. Factors
that have driven the market in North America are increasing prevalence
of cervical cancer cases, rapid technological advancements, and growing
awareness about malignant effects of cervical cancer among individuals.
In addition, various reimbursement policies related to the treatment of
cervical cancer would most likely fuel the growth of the market in the
next few years. However, Asia Pacific is projected to witness the
highest growth rate over the forecast period from 2014 to 2020. The
rationale behind such growth has been attributed to fast growing
consumer market, favorable government support for improved healthcare
infrastructure such as hospitals and clinics, and increasing awareness
among the population in the developing regions. Moreover, easy market
penetration, tax benefits and low labor costs would trigger the growth
of the market in the Asia Pacific region.
Major players operating in the cervical
cancer diagnostic tests market are Abbott Laboratories, Becton,
Dickinson and Company, and Hologic, Inc. Other companies include Guided
Therapeutics, Femasys, Inc., OncoHealth Corp., Quest Diagnostics, Inc.,
Roche Diagnostics, QIAGEN, and Zilico Ltd.
No comments:
Post a Comment